Biren Amin
Stock Analyst at Piper Sandler
(3.31)
# 1,027
Out of 5,112 analysts
66
Total ratings
50.85%
Success rate
3.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Overweight | $7 | $1.98 | +253.54% | 1 | Nov 25, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $28.61 | +67.76% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $20.34 | -21.34% | 12 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $93 → $98 | $74.14 | +32.18% | 4 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $51 → $67 | $17.07 | +292.50% | 2 | Oct 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $21 → $31 | $12.98 | +138.83% | 2 | Oct 3, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Overweight | $76 → $95 | $65.99 | +43.96% | 2 | Sep 25, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $3.08 | +94.81% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $1.15 | +247.83% | 1 | Jun 26, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $5.28 | +221.97% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $1.42 | +392.96% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $24.85 | +52.92% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $5.04 | +138.10% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $33.95 | +109.13% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.10 | +332.10% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $19.95 | +5.26% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $64.13 | +79.32% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $24.48 | +30.72% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.51 | -14.53% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.42 | +4,829.58% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.79 | +6,338.58% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $5.01 | +379.04% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $5.45 | +523.85% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.58 | +86,315.49% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $9.57 | +46.29% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $748.71 | -7.71% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $3.88 | +157.73% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $47.53 | +112.50% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $141.84 | -51.35% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $447.38 | -65.35% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $3.87 | +3,414.21% | 4 | Mar 6, 2017 |
Opus Genetics
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $1.98
Upside: +253.54%
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $28.61
Upside: +67.76%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $20.34
Upside: -21.34%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $74.14
Upside: +32.18%
LENZ Therapeutics
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $17.07
Upside: +292.50%
Ocular Therapeutix
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $12.98
Upside: +138.83%
Monopar Therapeutics
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $65.99
Upside: +43.96%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $3.08
Upside: +94.81%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $1.15
Upside: +247.83%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $5.28
Upside: +221.97%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.42
Upside: +392.96%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $24.85
Upside: +52.92%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $5.04
Upside: +138.10%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $33.95
Upside: +109.13%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $8.10
Upside: +332.10%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $19.95
Upside: +5.26%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $64.13
Upside: +79.32%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $24.48
Upside: +30.72%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.51
Upside: -14.53%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.42
Upside: +4,829.58%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.79
Upside: +6,338.58%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $5.01
Upside: +379.04%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $5.45
Upside: +523.85%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.58
Upside: +86,315.49%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $9.57
Upside: +46.29%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $748.71
Upside: -7.71%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $3.88
Upside: +157.73%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $47.53
Upside: +112.50%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $141.84
Upside: -51.35%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $447.38
Upside: -65.35%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $3.87
Upside: +3,414.21%